CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that the Company will release its first quarter 2017 financial
results after market close on Monday, May 8, 2017.
Management will host a conference call at 4:30 p.m. ET that day to
discuss the Company's financial results and provide a general business
update. The conference call will be webcast live via the Internet and
will be available on the "Investors & Media" section of the Dicerna
The webcast will also be archived on the Company's website.
The call can also be accessed by dialing (855) 453-3834 or (484)
756-4306 (international), and referencing conference ID 7812180 prior to
the start of the call. After the conference call, a replay will be
available until May 15, 2017. To access the replay, please dial (855)
859-2056 or (404) 537-3406, and refer to conference ID 7812180.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative RNAi-based therapeutics for
diseases involving the liver, including rare diseases, chronic liver
diseases, cardiovascular diseases, and viral infectious diseases. The
Company is leveraging its proprietary GalXC™ RNAi technology platform to
build a broad pipeline in these core therapeutic areas, focusing on
target genes where connections between target gene and diseases are well
understood and documented. The Company intends to discover, develop and
commercialize novel therapeutics either on its own or in collaboration
with pharmaceutical partners. For more information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170501006089/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media